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Abstract
Background: In normal adult skeletal muscle, cell turnover is very slow. However, after an acute lesion or in chronic 
pathological conditions, such as primary myopathies, muscle stem cells, called satellite cells, are induced to proliferate, 
then withdraw definitively from the cell cycle and fuse to reconstitute functional myofibers.
Results: We show that Maged1 is expressed at very low levels in normal adult muscle but is strongly induced after 
injury, during the early phase of myoblast differentiation. By comparing in vitro differentiation of myoblasts derived 
from wild-type or Maged1 knockout mice, we observed that Maged1 deficiency results in reduced levels of p21CIP1/
WAF1, defective cell cycle exit and impaired myotube maturation. In vivo, this defect results in delayed regeneration of 
injured muscle.
Conclusions: These data demonstrate for the first time that Maged1 is an important factor required for proper skeletal 
myoblast differentiation and muscle healing.
Background
Skeletal muscle contains quiescent mononucleated myo-
genic cells, called satellite cells, that are able to proliferate
in response to injury and give rise to new functional myo-
fibers. Soon after a lesion, inflammatory cells such as
neutrophiles and macrophages are recruited at the dam-
aged site where they release growth factors and cytokines
that induce satellite cells to proliferate. The activated sat-
ellite cells divide asymmetrically to (1) reconstitute the
stock of stem cells and (2) provide myoblasts that will first
proliferate and then undergo myogenic differentiation
and maturation to form new muscle fibers. The new cells
can fuse between themselves or with existing fibers. Mus-
cle differentiation involves a cascade of muscle-specific
gene activation coordinated with irreversible withdrawal
from the cell cycle. The commitment of cells to the mus-
cle lineage and to progression through differentiation
requires the activation of a limited set of muscle-specific
transcription factors. These key factors are the basic
helix-loop-helix (bHLH) transcription factors MyoD,
Myf5, myogenin (MyoG) and MRF4, which are collec-
tively called myogenic regulatory factors (MRFs). The
MRFs activate their target genes by binding to the E-box
CANNTG consensus sequence [1-4]. Primary cultures of
newborn or adult skeletal muscles or established muscle
cell lines like C2C12 can be used to study myogenic dif-
ferentiation. These cells can be maintained as dividing
cells in serum rich medium (GM), but under the condi-
tion of mitogen deprivation, they exit the cell cycle in G1
to G0, express the repertoire of muscle-specific genes and
fuse to form syncytial myotubes [5,6]. MyoD is expressed
early after satellite cell activation. In dividing cells, its
function is repressed, but upon induction of differentia-
tion, its transcriptional activity is induced, and it governs
two distinct essential functions: (1) activation of muscle
specific genes, such as MyoG, and (2) induction of with-
drawal from the cell cycle by activation of the cell cycle
inhibitors p21CIP1/WAF1 and Rb [7,8].
Necdin, a member of the large family of Mage proteins,
has recently been reported to promote myoblast survival
and differentiation and to improve skeletal muscle regen-
eration [9,10]. Necdin has also been shown to protect
muscle fibers from tumor-induced wasting by interfering
with the TNF signaling cascade [11]. Maged1 (also called
Nrage and Dlxin1) is an X-linked Mage family member
that physically interacts with Necdin [12]. Although in
vitro studies have suggested a role for Maged1 in diverse
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biological functions, only its role in the apoptotic signal-
ing cascade emanating for the TNF receptor superfamily
member p75NTR (p75 NeuroTrophin Receptor) has been
confirmed in vivo so far [13-15]. Interestingly, data
obtained by high throughput expression analysis indicate
that the expression of MAGED1 RNA is upregulated in
the muscles of Duchenne muscular dystrophy (DMD)
patients, a condition in which muscle regeneration con-
comitantly occurs with the degeneration of myofibers
[16]. This observation and the fact that Maged1 physi-
cally interacts with Necdin encouraged us to investigate
the possible roles of Maged1 in muscle regeneration and
differentiation. Here, we show that Maged1 is transcrip-
tionally upregulated during myogenic differentiation and
that Maged1 deficiency results in deficient myoblast dif-
ferentiation and maturation, leading to delayed muscle
regeneration in vivo.
Results
Maged1 is induced early during myogenic differentiation
Microarray gene profiling indicated that Maged1 was
upregulated in skeletal biopsies from DMD patients when
c o m p a r e d  t o  u n a f f e c t e d  c o n t r o l s  [ 1 6 ] .  T o  d e t e r m i n e  i f
Maged1 was expressed in proliferating and/or differenti-
ating muscle cells, we first analyzed Maged1 RNA and
protein levels in myoblasts from the C2C12 cell line. Dif-
ferentiation of the myoblasts was induced by serum star-
vation and monitored by following expression of p21CIP1/
WAF1 and MyoG during a four-day period. We observed
that Maged1 was expressed in proliferating C2C12 cells
and that Maged1 RNA and protein levels increased,
respectively, up to three and two folds after induction of
differentiation. The levels of Maged1 reached a plateau 24
hours after serum starvation, at the time when the cells
withdraw from the cell cycle, and these elevated levels
were maintained until the end of the experiment, four
days after serum starvation (Figure 1A-B and Additional
file 1: Figure S1). We next analyzed expression of Maged1
in primary myoblast cultures derived from mouse tibialis
anterior (TA) muscle and found Maged1 protein
expressed in the proliferating cells. A two-fold induction
of Maged1 expression was also observed in these cells fol-
lowing differentiation by serum starvation (Figure 1C).
To determine if Maged1 is induced in vivo in regenerat-
ing muscle, we followed its expression during the course
of muscle healing after injection of cardiotoxin (CTX) in
TA muscles. Western blot analysis detected no or very lit-
tle Maged1 expression in intact mouse muscle, but the
protein was strongly induced as soon as 6 hours after
CTX injection (Figure 1D). This Maged1 upregulation
could emerge from muscle cells (mature myofibers and/
or activated satellite cells) or from non-muscle cells (e.g.
inflammatory cells or endothelial cells). To determine the
contribution of muscle cells to the observed induction,
we followed Maged1 expression after CTX injection in
T A  m u s c l e  o f  m i c e  w i t h  a  C r e - m e d i a t e d  d e l e t i o n  o f
Maged1 driven by the promoter of the human alpha-skel-
etal actin (HSA) gene, which is activated specifically in
differentiating muscle cells [17]. These Maged1tm1Urfm/
HSA-Cre mice were obtained by crossing mice with a condi-
tional (floxed) allele of Maged1 (Maged1tm1Urfm/tm1Urfm)
with transgenic mice carrying an HSA-Cre transgene
(Tg(ACTA1-cre)79Jme/J). In the resulting mice, Cre is
switched on and Maged1 is deleted specifically in differ-
entiating muscle myotubes [17]. The weaker induction of
Maged1 in these mice demonstrated that differentiating
and/or mature muscle cells contribute to the Maged1
induction after CTX injury (Figure 1E). The remaining
Maged1 expression most probably originates from mus-
cle cells that do not express Cre (e.g. activated satellite
cells and proliferating myoblasts) and/or from non-mus-
cle cells. Together, our results demonstrate in vitro and in
vivo induction of Maged1 in the course of myoblast dif-
ferentiation.
Maged1 transcription is activated by MRFs during myoblast 
differentiation
The myogenic differentiation program is regulated pri-
marily by the MRFs that all bind to E-box motifs in their
target gene promoters. These factors act in cooperation
with myocyte enhancer factor 2 (MEF2) and bHLH E
Figure 1 Maged1 is induced early during myogenic differentia-
tion. (A) Maged1, p21CIP1/WAF1 and MyoG RNA levels were determined 
using qRT-PCR during the differentiation of C2C12 myoblasts induced 
by serum starvation. RNA levels were normalized using GAPDH RNA as 
the reference. Data are presented as the relative folds of induction at 
different time points with respect to the level measured at the time of 
serum starvation (0 h). (B-E) Immunoblotting analysis of Maged1 in 
C2C12 myoblasts (B) and primary mouse myoblasts (C) during myo-
genic differentiation and in TA muscle regenerating after CTX injection 
in wild-type mice (D) and in Maged1tm1Urfm/HSA-Cre mice that have a cell-
type specific deletion of Maged1 in myoblasts (E). Induction of Maged1 
was quantified by digital imaging using alpha-tubulin for normaliza-
tion (B and C).Nguyen et al. BMC Cell Biology 2010, 11:57
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proteins to drive the myogenic differentiation program.
In C2C12 myoblasts, MyoD is expressed but is inactive
when cells are cultured in serum-rich medium [18,19].
Upon serum starvation, MyoD is activated and triggers
the myogenic differentiation program by transactivating
its target genes, including MyoG. The early upregulation
of  Maged1  RNA after serum starvation suggested that
Maged1 transcription could be regulated by MyoD. We
analyzed the promoter region of the human MAGED1
gene (from -1977 to +80) in silico and compared it with
the orthologous regions of distant species of mammals:
M. musculus, S. scrofa and C. familiaris. We found that
the MAGED1 promoter of all of these species contains
four conserved E-boxes located in two conserved regions,
suggesting that these sites could be important for the
control of Maged1 transcription (Figure 2A).
To test this hypothesis, the DNA fragment from -1977
to +80 of the human MAGED1 promoter was inserted
upstream of the firefly luciferase reporter gene and tested
for  cis-activation in proliferating and differentiating
C2C12 myoblasts. We found that the luciferase activity
controlled by this fragment increased approximately ten
fold 24 hours after the induction of differentiation by
serum starvation. To localize the key regulatory elements
in this fragment, we deleted segments from its 5' end and
found that the -531+80 fragment had nearly the same
activity as the -1977+80 fragment (Figure 2A-B). This
indicates that the two proximal E-boxes at -227 and -118
(especially the box at -118, which is conserved in mam-
mals) are possible important sites for transcriptional
induction. We tested the importance of these two E-
boxes by targeted mutagenesis. Mutation of the -118 E-
box resulted in a significant reduction of induction after
serum starvation, indicating that this site is important for
induction and that MRFs are probably directly involved
(Figure 2C). We then tested the potential of transfected
MyoD to transactivate the -531+80 fragment in NIH-3T3
cells, which do not express endogenous MyoD. MyoD
induced a three-fold increase in the expression of the
luciferase reporter (Figure 2D and Additional file 2: Fig-
ure S2). Altogether, these results show that the MAGED1
promoter is activated upon the induction of myoblast dif-
ferentiation and contains conserved E-boxes that are
important for its transactivation by MyoD.
Deficiency of Maged1 results in impaired myogenic 
differentiation
The induction of Maged1 during myoblast differentiation
and the fact that the related protein Necdin promotes
myoblast differentiation suggested that Maged1 could
also be a regulator of myogenic differentiation. To investi-
gate this possibility, we compared differentiation of pri-
mary myoblasts isolated from wild-type or from
constitutive Maged1 knockout mice [14]. We observed
that wild-type myoblasts differentiated and matured to
form myotubes 48 hours after serum starvation. In con-
trast, very few and very thin myotubes were formed by
Maged1-deficient myoblasts at this time point (Figure
3A). We quantified this deficiency to form myotubes by
calculating the fusion index (the fraction of nuclei present
in multinucleated myotubes) 24 hours and 48 hours after
serum starvation. As shown in Figure 3B, we observed a
dramatic reduction of the fusion index at these two time
points, confirming that Maged1 is essential for the fusion
of myoblasts in these conditions (Figure 3B). Using qRT-
PCR, we also followed the expression of embryonic myo-
sin heavy chain (eMHC) and muscle creatine kinase
(MCK), two late markers of myoblast differentiation. We
observed that the impaired morphological differentiation
of the Maged1-deficient myoblasts was accompanied by a
largely reduced induction of these two markers (Figure
3C). We then analyzed the regeneration capacity of
injured muscle in mice with the HSA-Cre mediated dele-
Figure 2 The MAGED1 promoter is activated during myogenic dif-
ferentiation and contains two E-boxes required for MyoD-depen-
dent transcription. (A) Three promoter fragments of the human 
MAGED1 gene were amplified using PCR and inserted upstream from 
the firefly Luc reporter gene into pGL3-basic. Regions of the promoter 
conserved in mammals are boxed. E-box consensus sequences are in-
dicated by vertical boxes (black if conserved in mammals). Coordinates 
are shown with respect to the first nucleotide of the MAGED1 tran-
script. (B) The 3 reporter constructs (pMAGED1-1977+80-luc, 
pMAGED1-971+80-luc, pMAGED1-531+80-luc) were used to transfect 
C2C12 myoblasts. Twenty-four hours after transfection, cells were shift-
ed to DM and cultivated for another 24 hours before luciferase activity 
quantification. Firefly luciferase activity was normalized by the Renilla 
luciferase activity specified by a Renilla luciferase expression plasmid 
(pRL-CMV) co-transfected with the MAGED1-luc constructs. Results are 
presented as relative luciferase activity with respect to the activity of 
the MAGED1-1977+80-luc construct at the time of serum starvation (t 
= 0 h). (C) Effect of mutation of the -227 and -118 E-boxes on the lu-
ciferase activity of pMAGED1-531+80-luc. Experimental procedure was 
the same as in B. (D) Effect of MyoD on the promoter activity of the -
531+80 fragment with intact or mutated -227 and -118 E-boxes. 3T3 fi-
broblasts were transfected with the MAGED1-luc constructs with or 
without the MyoD expression plasmid pEMSV-MyoD. Results are pre-
sented as relative luciferase activities with respect to the activity of the 
promoter fragments in absence of MyoD.Nguyen et al. BMC Cell Biology 2010, 11:57
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tion of Maged1 (Maged1tm1Urfm/HSA-Cre). Although no
overt morphological abnormality was observed in the
untreated Maged1-deficient muscles, we observed that
muscle regeneration was significantly delayed: five days
after CTX injection in the TA muscle, fewer and smaller
new myofibers had been formed and the laminin scaffold
was much more disorganized when compared to controls
(Figure 3D-E). We quantified this defect by measuring the
cross-sectional area of the new muscle fibers and found
that it was reduced by 47% in Maged1tm1Urfm/HSA-Cre mice
compared to controls (44 ± 7 μm2 vs. 82 ± 9 μm2). Two
days later (7 days after CTX injection), the difference
between wild-type and Maged1tm1Urfm/HSA-Cre had become
smaller (Figure 3D-E). Altogether, these observations
demonstrate that Maged1 is essential for myoblast differ-
entiation in vitro and that Maged1 deficiency delays mus-
cle regeneration in vivo.
Maged1 is required for normal p21CIP1/WAF1 expression and 
cell cycle withdrawal of differentiating myoblasts
Reduced differentiation could result from deficient
expression of MRFs or from an inability to withdraw from
the cell cycle in G0. To identify the cause of the differenti-
ation defect observed in the myoblasts derived from con-
stitutive Maged1 knockout mice, we analyzed the
expression of p21CIP1/WAF1, MyoD, MyoG and Mef2C by
qRT-PCR. We did not detect significant differences in the
levels of MyoD, MyoG and Mef2C between knockouts and
c o n t r o l s  ( A d d i t i o n a l  f i l e  3 :  F i g u r e  S 3 ) .  H o w e v e r ,  w e
observed a reduced level of p21CIP1/WAF1 mRNA in both
proliferating and differentiating Maged1 knockout myo-
blasts (Figure 4A). p21CIP1/WAF1 facilitates cell cycle with-
drawal and enhances the survival of differentiating
myoblasts [20,21]. We hypothesized that the reduced
level of p21CIP1/WAF1 in Maged1-deficient myoblasts could
impair cell cycle withdrawal. To test this possibility, we
compared the cell cycle distribution of wild-type and
Maged1-deficient myoblasts upon induction of the differ-
entiating. FACS analysis showed no difference in cell
cycle profiles in serum rich medium. However, 24 hours
after serum starvation, the fraction of cells in S phase was
three times greater in the Maged1-deficient cell popula-
Figure 3 Deficiency of Maged1 results in impaired myogenic dif-
ferentiation. (A) Primary myoblasts derived from wild-type or Maged1 
knockout mice were cultivated on collagen-coated plates and induced 
to differentiate by serum starvation. Cells were stained with anti-MHC 
antibody. Images were photographed under a light microscope. Scale 
bar, 100 μm. (B) The fusion index was calculated by dividing the num-
ber of nuclei in MHC-positive cells containing at least 2 nuclei by the 
total number of nuclei in MHC-positive cells. (C) eMHC and MCK RNA 
levels during differentiation were analyzed using qRT-PCR. Data are 
presented as the relative folds of induction with respect to wild-type 
myoblasts at the time of serum starvation (t = 0 h). GAPDH RNA was 
used for the normalization. (D) Representative sections analyzed by 
H&E staining of TA muscles of Maged1tm1Urfm/HSA-Cre mice after CTX in-
jection. Arrows indicate newly formed myotubes. Scale bar, 50 μm. (E) 
Laminin expression (red) analyzed by immunostaining of TA muscles 
of Maged1tm1Urfm/HSA-Cre mice after CTX injection. Nuclei were visualized 
by Hoechst 33342. Scale bar, 50 μm.
Figure 4 Maged1 knockout myoblasts have a lower p21CIP1/WAF1 
expression level and fail to properly exit from the cell cycle. Wild-
type and Maged1 knockout primary myoblasts were induced to differ-
entiate by serum starvation. (A) The p21CIP1/WAF1 RNA level was quanti-
fied by qRT-PCR. GAPDH RNA was used for normalization. Data are 
presented as the ratio relative to the p21CIP1/WAF1 RNA level in wild-type 
cells at the time of serum starvation (t = 0 h). (B) Fractions of wild-type 
and Maged1-deficient myoblasts in S phase in GM (0 h) and 24 h after 
serum starvation. Cells were analyzed by FACS after staining with pro-
pidium iodide. (*p < 0.01). (C) BrdU incorporation of differentiating 
myoblasts was analyzed after 24 h in DM. Data are presented as the 
fraction of BrdU-labeled cells. (*p < 0.01).Nguyen et al. BMC Cell Biology 2010, 11:57
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tion when compared to the wild-type control cells (Figure
4B). BrdU incorporation confirmed that Maged1-defi-
cient myoblasts do not exit the cell cycle efficiently upon
serum starvation: twice as many Maged1 deficient cells
incorporated BrdU compared to wild-type cells (Figure
4C). We concluded that Maged1 knockout myoblasts
cannot exit the cell cycle efficiently after the induction of
differentiation.
Discussion and Conclusions
Skeletal muscle satellite cells are quiescent stem cells that
are activated in response to physiological or pathological
stimuli such as after muscle injury or in chronic patho-
logical conditions. After an acute lesion, the initial phase
of muscle repair is characterized by inflammation and
degeneration of the damaged tissue. Almost simultane-
ously, satellite cells are activated and proliferate to gener-
ate a population of myoblasts that differentiate and fuse
to form new multinucleated myotubes. Muscle regenera-
tion is a tightly orchestrated process, and understanding
the molecular and cellular mechanisms responsible for its
control is important for the development of treatments of
muscles impaired by aging, disease or atrophy.
Maged1 is upregulated during myoblast differentiation 
and muscle regeneration
Maged1 is silent in normal adult muscles, but it is mas-
sively induced soon after injury of skeletal muscles. In
primary cultures of myoblasts, Maged1 is expressed in
proliferating cells, and its expression increases within the
first 24 hours after the induction of terminal differentia-
tion at the time when cells normally exit from the cell
cycle. We observed that high levels of Maged1 RNA and
protein were maintained as long as the differentiation
proceeded. Promoter analysis showed that Maged1 tran-
scription was upregulated during myogenic differentia-
tion and that two E-boxes present in the proximal
promoter were responsible for this activation. This
strongly suggests that MyoD and/or other MRFs is (are)
responsible for this regulation.
Maged1 is required for efficient myoblast cell cycle 
withdrawal, myogenic differentiation and normal muscle 
regeneration after injury
The induction of Maged1 during muscle differentiation
and regeneration suggested that it could play a role dur-
ing these processes. We showed that mouse primary
myoblasts deficient in Maged1 had a largely reduced
capacity to differentiate and to fuse. In vivo, the loss of
Maged1 leads to delayed regeneration after muscle injury
with the production of smaller muscle fibers. This deficit
appears to result from a late block in the differentiation
program. Indeed, in the absence of Maged1, we observed
normal expression of MyoD and MyoG, which are early
differentiation markers expressed in proliferating cells,
whereas the late markers eMHC  (a muscle structural
gene) and MCK (an important muscle kinase) were not
induced properly. The mechanism responsible for this
deficit remains to be fully elucidated, but the reduced
ability of the cells to establish the G0 arrest probably con-
tributes to the impaired differentiation. A similar obser-
vation was made in P19 embryonic carcinoma cells
differentiating in neurons after treatment with retinoic
acid: downregulation of Maged1 by morpholinos dis-
turbed neurogenesis by impairing cell cycle withdrawal
[22]. Maged1 thus appears to be a key component regu-
lating the transition of progenitors to differentiated neu-
rons and muscle cells by interfering with the cell cycle
progression.
A future direction of inquiry following these results will
be to determine how Maged1 regulates the G1 to G0
transition in differentiating myoblasts. This cell cycle
arrest requires the retinoblastoma tumor suppressor (Rb)
protein [23,24]. The precise mechanisms leading to the
activation of Rb during myogenesis remain unclear . Rb
activity is controlled by its phosphorylation by cyclin-
dependent kinases (Cdk), which are in turn controlled by
Cdk inhibitors, including p21CIP1/WAF1 [25]. In differenti-
ating myoblasts, p21CIP1/WAF1  transcription is directly
controlled by members of the p53 family [26]. Indeed,
ectopic expression of ΔNp73, a transdominant inhibitor
of all p53 members (p53, p63 and p73) prevents p21CIP1/
WAF1 induction, cell cycle withdrawal and myogenic dif-
ferentiation [26]. The fact that p53 knockout mice exhibit
normal muscle development excludes an essential role for
this protein in myogenic differentiation and points at p63
and/or p73 as the key factors in this process [26,27].
Additionally, it has been shown that overexpression of
Maged1 in HEK293 cells activates p53-dependent trans-
activation of the p21CIP1/WAF1 promoter [28]. As p21CIP1/
WAF1  expression is reduced in Maged1-deficient myo-
blasts, we can hypothesize that Maged1 acts as a tran-
scriptional cofactor of p63 and/or p73 to promote
p21CIP1/WAF1 expression and cell cycle exit. Alternatively,
Maged1 could act indirectly, by sequestering an inhibitor
of p63 and/or p73 activity. Such a mechanism has been
shown for Necdin, which sequesters EID-1, an E1A-like
protein that inhibits MyoD by suppressing the acetyl-
transferase activity of its transcriptional co-activator
p300 [29].
It has been shown previously that Maged1 can regulate
transcription by interacting with several transcription
factors and regulators [30-33]. Besides its involvement in
the regulation of cell proliferation through p21CIP1/WAF1
expression, Maged1 could directly or indirectly regulate
other genes essential for the skeletal myogenic differenti-
ation. A role for Maged1 in cell adhesion has beenNguyen et al. BMC Cell Biology 2010, 11:57
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reported by Xue et al. [34], we could therefore imagine
that deficient cell adhesion and/or fusion could also par-
ticipate in the observed muscle phenotype.
Maged1 is broadly expressed in embryonic and adult
tissues and has been identified as interacting with many
proteins implicated in apoptosis signaling, cell cycle regu-
lation, cell adhesion and migration, cell differentiation
and transcription regulation [12,22,28,31,34-41]. How-
ever, the physiological relevance of these interactions
remains largely to be demonstrated. We have produced
Maged1 knockout mice and have shown previously that
Maged1 acts as a pro-apoptotic factor required for nor-
mal developmental apoptosis of sympathetic, sensory and
motor neurons in vivo [14]. Here, we show that Maged1
plays an important role in myogenic differentiation by
allowing myoblasts to express appropriate levels of
p21CIP1/WAF1, exit the cell cycle and undergo terminal dif-
ferentiation.
Methods
Antibodies and chemicals
The following reagents were purchased as indicated:
mouse anti-Nrage (cat. 612500) and mouse anti-BrdU
(cat. 555627) from BD Sciences; rabbit anti-MHC from
Santa Cruz (cat. Sc-20641); rabbit anti-laminin (cat.
L9393) from Sigma-Aldrich; fluorescent secondary
Alexa-conjugated antibodies from Invitrogen; horserad-
ish peroxidase-conjugated secondary antibodies from
Dako; cell culture media and sera from Lonza Inc.; Dual
Luciferase Reporter Assay kit from Promega; Hoeschst
33342 (cat. H1399) and TOPRO®-3 (cat. T3605) from
Invitrogen; Vectastain ABC kit from Vector Laboratories;
other chemicals from Sigma-Aldrich.
Animals and primary myoblast cell culture
Mice with the conditional floxed allele (Maged1tm1Urfm)
and the Cre-recombined (constitutive knockout) allele for
Maged1 have been described previously [14].
Maged1tm1Urfm/HSA-Cre mice lacking Maged1 only in differ-
entiating muscle cells were obtained by crossing mice
with a floxed Maged1 allele (Maged1tm1Urfm/tm1Urfm) with
transgenic mice specifically expressing Cre recombinase
in differentiating myoblasts (Tg(ACTA1-cre)79Jme/J)
t h a t  w e r e  o b t a i n e d  f r o m  t h e  J a c k s o n  L a b o r a t o r y  [ 1 7 ] .
Animals were maintained and treated in compliance with
the guidelines specified by the Belgian Ministry of Trade
and Agriculture (agreement LA 1900056). Primary myo-
blasts were isolated from the adult tibialis anterior (TA)
muscle of two- to three-month old wild-type or constitu-
tive Maged1 knockout mice following the protocol of the
Springer Lab (University of California, San Francisco),
which was adapted from the protocol of Springer, M.L., T.
Rando, and H.M. Blau (1997) « Gene delivery to muscle »
in Current Protocols in Human Genetics (John Wiley &
Sons, New York). Cells were grown on collagen-coated
plates, either in proliferation medium (Ham's F-10 sup-
plemented with 20% FBS, 2.5 ng/ml bFGF, and 50 μg/ml
gentamycin) or in differentiation medium (DMEM sup-
plemented with 5% horse serum, 50 μg/ml gentamycin).
Histology and morphometry
TA muscles of Maged1tm1Urfm/HSA-Cre and Maged1tm1Urfm
adult mice (2-4 months) were injected with 50 μl of 10
μM cardiotoxin (CTX) (from Naja mossambica mossam-
bica, C9759 - Sigma-Aldrich) and harvested at the indi-
cated time points. Muscles were fixed in Bouin's solution
(for hematoxylin and eosin) or in 4% buffered paraform-
aldehyde solution (for immunostaining) and were paraf-
finized following standard protocol. For histological
analysis, 6-μm serial sections were stained with hematox-
ylin and eosin according to standard protocol. To calcu-
late the cross-sectional area of myofibers (XSA), three
images were captured from each section and the surface
of at least 800 myofibers per genotype per time point
were measured using MATLAB (The MathWorks). Lami-
nin immunostaining was performed on 6-μm sections
following the instructions of the manufacturer. Nuclei
were visualized by counterstaining with Hoeschst 33342.
Cell lines and plasmids
C2C12 myoblasts were a gift from Professor Raymackers
(UCL, Louvain-la-Neuve, Belgium). C2C12 cells were
maintained in DMEM supplemented with 20% FBS, 50
μg/ml gentamicin, and a 1x mixture of non-essential
amino acids (growth medium, GM). Cells were induced
to differentiate in DMEM supplemented with 2% horse
serum and 50 μg/ml gentamicin (differentiation medium,
DM). NIH-3T3 fibroblasts were cultured in DMEM sup-
plemented with 10% FBS and 50 μg/ml gentamicin.
The MyoD expression plasmid pEMSV-MyoD (original
r e s e a r c h e r  A p r i l  H a w k i n s )  w a s  a  k i n d  g i f t  o f  E r i c  N .
Olson. Fragments of the human MAGED1 promoter and
their mutated versions were amplified by PCR from
human DNA and cloned into a pGL3-basic vector (Pro-
mega). Site-directed mutagenesis was performed using a
triple PCR method. The primers used were the following:
-1977 forward: 5'-TCAGAGCTCTATGAAGGAATCG-
GTTTGGGA-3'; -971 forward: 5'-TCAGAGCTCTTAGT
CCCCAGGCCAGCATGA-3'; -531 forward: 5'-TCA-
GAGCTCTCCTCTCAGGCCATTCCGTT-3'; +80 reverse:
5'-TCAACGCGTGAGGATCGGGATTGCTGGGC-3';
Δ-118 forward: 5'-TCCAGCGCACACGAGCATCATG-
GTCT-3'; Δ-118 reverse: 5'-AGACCATGATGCTCGT-
GTGCGCTGGA-3'; Δ-227 forward: 5'-GCACAGCGTAT
CCGTCGGGGAGG-3'; Δ-227 reverse: 5'-CCTCCCCG
ACGGATACGCTGTGC-3'. Italic sequences indicate E-
boxes and letters in bold indicate mutated nucleotides.Nguyen et al. BMC Cell Biology 2010, 11:57
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qRT-PCR
Total RNA from cells from 6-cm plates was extracted
using the RNeasy mini kit (Qiagen) and subjected to
reverse transcription using the Impromt-II transcriptase
(Promega) according to the manufacturer's instructions.
Quantitative PCR was performed on 7.5 ng of cDNA in a
volume of 20 μl with Power SYBR Green PCR Master Mix
(Applied Biosystems) using the ABI 7300 real-time PCR
System (Applied Biosystems). Unless otherwise cited,
primer sequences were designed using Primer Express
software (Applied Biosystems).
The primers used were the following: GAPDH forward:
5'-CGTGCCGCCTGGAGAA-3'; GAPDH reverse: 5'-
GATGCCTGCTTCACCACCTT-3'; Maged1 forward: 5'-
CAAGAGGACCCGCAAGGTT-3'; Maged1 reverse: 5'-
GCCTTTGATCCCCACTGTTG-3'; MyoD forward: 5'-
GCTGCCTTCTACGCACCTG-3'; MyoD reverse: 5'-
GCCGCTGTAATCCATCATGC-3' [42]; MyoG forward:
5'-CCTGGAAGAAAAGGGACTGG-3'; MyoG reverse:
5'-TCATTCACTTTCTTGAGCCTGC-3' [43]; Mef2C
forward: 5'-TGGAGAAGCAGAAAGGCACT-3'; Mef2C
reverse: 5'-ATTCGTTCCCTCTGCACTTCT-3'; p21 for-
ward: 5'-GGTGGTGGAGACCTGATGAT-3'; p21 reverse:
5'-GCACCTTTTATTCTGCTGGC-3'; eMHC forward:
5'-TGAAGAAGGAGCAGGACAC-CAG-3'; eMHC
reverse: 5'-CACTTGGAGTTTATCCACCAGATCC-3'
[11]. MCK forward: 5'-GATTCTCACTCGCCTTCGTC-3';
MCK reverse: 5'-GCCCTTTTCCAGCTTCTTCT-3' [44].
Luciferase Assay
5x104  NIH-3T3 fibroblasts or C2C12 myoblasts were
seeded into each well of 24-well plates and transfected
with 1 μg of DNA mixtures, including 20 ng of the Renilla
luciferase-encoding plasmid pRL-CMV using ExGen500
and Turbofect reagent (Fermentas, Germany), respec-
tively. To determine the activity of MAGED1 during dif-
ferentiation in C2C12 myoblasts, 980 ng of pMAGED1-
1977+80-luc, pMAGED1-971+80-luc or pMAGED1-
531+80-luc plasmids were used for each transfection. To
analyze the effect of MyoD on the activity of MAGED1
promoter in 3T3 fibroblasts, increasing amounts of the
MyoD expression plasmid pEMSV-MyoD were cotrans-
fected with 380 ng of pMAGED1-531+80-luc plasmid.
Empty vector (pEMSV) was used as a substitute for
pEMSV-MyoD if needed to maintain a constant total
amount of transfected DNA. In experiments with
mutated MAGED1 promoters in fibroblasts, 600 ng of
pEMSV-MyoD or pEMSV were cotransfected with 380
ng of pMAGED1-531+80-luc plasmid or its mutated ver-
sions. Cells were harvested at the indicated time points
and subjected to luciferase measurement using the Dual
Luciferase Reporter Assay kit (Promega). Firefly luciferase
activities were normalized to Renilla luciferase activities.
FACS and cell cycle analysis
Cells were harvested by trypsinization, fixed in 70% etha-
nol overnight at -20°C and incubated with propidium
iodide (PI) solution (PI 10 μg/ml, sodium citrate 1.1% and
RNAse A 1 mg/ml) for 30 minutes at 37°C before FACS
analysis. For each sample, 10,000 cells were analyzed for
DNA content in the FL2 channel using FACSCalibur plat-
form (BD Sciences).
Immunocytochemistry and fusion index
First, 5x104 primary myoblasts were seeded in each well
of 24-well collagen-coated plates in GM. Twenty-four
hours later, cells were shifted to DM. To perform immu-
nocytochemistry, cells were fixed in 4% buffered para-
formaldehyde solution and incubated with anti-MHC for
two hours at room temperature. MHC-expressing cells
were visualized using the Vectastain ABC kit (Vector
Laboratories). Labeled cells were photographed under a
light microscope, and more than 800 nuclei per genotype
per time point were counted. The fusion index was calcu-
lated by dividing the number of nuclei in MHC-express-
ing cells containing at least two nuclei by the total
number of nuclei of MHC-expressing cells.
BrdU incorporation test
Cells were incubated for 2 hours with BrdU-containing
medium (10 μM) before staining with anti-BrdU and sec-
ondary fluorescent antibodies following standard proto-
col. Nuclei were visualized by counterstaining with
TOPRO®-3. Approximately 400 cells were counted under
fluorescent microscopy to determine the percentage of
labeled cells.
Protein extraction and immunoblot analysis
Cells and muscle tissues were homogenized in RIPA buf-
fer containing 50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25%
Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
NaF, 1 mM Na3VO4, and a protease inhibitor cocktail
(Complete; Roche Diagnostics) and centrifuged at 1,000 g
for 10 min at 4°C to discard cellular debris. The protein
concentration was measured using the Pierce® BCA Pro-
tein Assay Kit. Sample preparation and western blot anal-
ysis were performed following standard protocol.
Chemiluminescent signals were quantified by digital
imaging using the Imagequant 350 system (General Elec-
tric)."
Statistical analysis
All experiments were performed at least three times and
results were expressed as mean ± the standard deviation
(SD). Statistical analyses were conducted using Student's
t-test and the difference was considered significant when
the probability value was < 0.05.Nguyen et al. BMC Cell Biology 2010, 11:57
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